Provention Bio, Inc. (PRVB)
Stock Price:
$12.84 USD
0.78 (6.47%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
722.64M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-55.01M |
| Shares Out |
56.28M |
| EPS (ttm) |
-1.19 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 22, 2020 |
| Last Price |
$12.84 |
| Previous Close |
$12.06 |
| Change ($) |
0.78 |
| Change (%) |
6.47% |
| Day's Open |
12.04 |
| Day's Range |
12.04 - 12.93 |
| Day's Volume |
341,362 |
| 52-Week Range |
4.72 - 18.50 |
More Stats
| Market Cap |
722.64M |
| Enterprise Value |
550.48M |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
56.28M |
| Float |
45.37M |
| EPS (basic) |
-1.16 |
| EPS (diluted) |
-1.19 |
| FCF / Share |
-0.93 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
4.57M |
| Short Ratio |
6.83 |
| Short % of Float |
10.08% |
| Beta |
3.53 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
4.59 |
| Revenue |
n/a |
| Operating Income |
-56.52M |
| Net Income |
-55.01M |
| Free Cash Flow |
-45.71M |
| Net Cash |
172.16M |
| Net Cash / Share |
3.06 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-32.38% |
| ROE |
-54.69% |
| ROIC |
-243.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (7)
| Buy |
7 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$28.00*
(118.07% upside)
Low
25.0
Current: $12.84
High
35.0
Target: 28.00
*Average 12-month price target from 7 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | - | - | - |
| Operating Income | -44.37 | -26.81 | -9.14 |
| Net Income | -43.29 | -26.48 | -9.13 |
| Shares Outstanding | 40.75 | 22.44 | 9.37 |
| Earnings Per Share | -1.06 | -1.19 | -1.01 |
| Operating Cash Flow | -36.07 | -22.64 | -4.88 |
| Free Cash Flow | -36.07 | -22.64 | -4.88 |
| Cash & Equivalents | 85.37 | 58.54 | 21.83 |
| Net Cash / Debt | 85.37 | 58.54 | 21.83 |
| Assets | 86.00 | 61.53 | 22.43 |
| Liabilities | 3.84 | 1.87 | 2.28 |
| Book Value | 82.16 | 59.66 | -6.03 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Provention Bio, Inc. |
| Country |
United States |
| Employees |
19 |
| CEO |
Ashleigh W. Palmer |
Stock Information
| Ticker Symbol |
PRVB |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: PRVB |
Description
Provention Bio, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, an oral CSF-1R inhibitor, which is in Phase IIa clinical trial for the treatment of Crohn's disease; PRV-3279, which has completed Phase 1b clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease. Provention Bio, Inc. was incorporated in 2016 and is based in Oldwick, New Jersey.